Table 5.
Overview of solubility enhancement reported for co-crystal drugs.
| # | Solubility Evaluation (UV, HPLC) | Sample | Folds | Ref. |
|---|---|---|---|---|
| 3C | In vitro | Ciprofloxacin-thymol (1:2) | 4 | [118] |
| 5C | UV | Brexpiprazol-catechol (1:1) | 2.5 | [120] |
| Brexpiprazol-succinic acid (1:1) | 2.5 | |||
| 6C | UV | Quercetin-malonic acid (1:2) | 1.056 | [121] |
| 7C | UV | Paracetamol-trimethylglycine * (1:1) | 0.82 | [44] |
| 11C | UV | Ciprofloxacin-nicotinic acid (1:1) | 20 (in water) | [124] |
| 1.5 | ||||
| Ciprofloxacin-isonicotinic acid (1:1) | 20 | |||
| 2.5 | ||||
| 13C | HPLC | Acetazolamide-4-aminobenzoic acid * (1:1) | 2.5 | [67] |
| 2.17 | ||||
| 15C | IDR | β-lapachone-resorcinol (1:1) | 2 | [127] |
| 16C | UV | Norfloxacin-nicotinic acid (with EtOH) pH = 3 | No change | [128] |
| Norfloxacin-nicotinic acid (with EtOH) pH = 6.1 | 2 | |||
| Norfloxacin-nicotinic acid (with EtOH) pH = 8.5 | <2 | |||
| 17C | UV (Powder dissolution) | Chlorothiazide-DL-proline (w/acetonitrile-water) | 1.05 | [129] |
| Chlorothiazide-L-proline hydrate (w/acetonitrile-water) | Lower value than the initial drug | |||
| Chlorothiazide-D-proline hydrate (w/acetonitrile-water) | ||||
| 19C | HPLC (In vitro release test) | Ferulic acid-nicotinamide | 2.4 | [131] |
| Ferulic acid-isonicotinamide | 3.1 | |||
| Ferulic acid-urea | 1.1 | |||
| 21C | HPLC | Itraconazole-4-hydroxybenzamide form II (1:2) | 225 | [133] |
| Itraconazole-4-aminobenzoic acid (1:1) | 64 |